Reported about 1 month ago
Sanofi's sale of its consumer health business Opella for €16 billion to US firm Clayton Dubilier & Rice has led to a heated public feud, political backlash, and fierce competition with rival PAI Partners. Despite criticisms regarding job security and national interests, Sanofi ultimately opted for CD&R, citing better resources for expansion and growth potential. The intense scrutiny and political implications surrounding this high-stakes transaction reveal the complexities of European deal-making and the challenges posed by national sovereignty concerns.
Source: YAHOO